Woody: Waste Aplenty in Trial ‘Coordinating’ Activities


By Deborah Borfitz

August 18, 2008 | Clinical investigators like the idea of collecting patient data once and using it for both medical care and research purposes. In academic settings, many faculty members adequately handle the task with some sort of homegrown electronic data collection (EDC) system, points out Stephen Woody, associate chief information officer for clinical and translational research for Duke Medicine.

Although the wholesale integration of EDC with electronic medical records (EMRs) is many years off, says Woody, it’s only sensible to improve the workflow of data collection in the interim. The business of study monitoring and site management could also use an efficiency boost. A study conducted by Eric Eisenstein, DBA, assistant professor of medicine at the Duke Clinical Research Institute (DCRI), found that 60 percent of sponsor dollars were consumed by such “coordinating” activities. The more that figure can be slashed, Woody adds, the more money will be available to do additional research and better compensate high-enrolling sites.

Information collection is financially stymied by concerns that data be pristinely clean, or at least be perceived as such by the FDA. “Early on, the DCRI didn’t want to touch clinical data,” says Woody. “It was seen as too dirty and not adequately defined.” As it turns out, “clean data means [surprisingly] little to an adequately powered study.”

 Stephen Woody 
Stephen Woody
Meanwhile, progress is being made by DCRI and government initiatives such as the Cancer Biomedical Informatics Grid (caBIG) to develop a common language to more easily share information across disparate sites and information systems. The Clinical Data Interchange Standards Consortium (CDISC) also has two initiatives to enhance the healthcare-research interface.

EDC vendors have a vested interest in keeping the “dirty data” myth alive, says Woody, because the systems they sell generally have “query rules” for picking up data inconsistencies that so trouble FDA-wary sponsors. Clinical research organizations, DCRI among them, also “seem to feed off the inefficiencies of how we do clinical research. Technology needs to take over what humans do now to free them up for higher value work.”

A statistical method also needs to be developed for study monitoring in lieu of “putting people on planes all over the world,” continues Woody. “For the time spent, not much work gets done.”

Much work remains to be done before clinical and research data can have a common collection point, says Woody. The first problem is that information collected in the clinical setting is not “scoped appropriately” to meet the demands of research protocols. “Angina is a general term that could be used by doctors in different ways,” he offers as an example. “But for a protocol, it may be defined in excruciating detail.”

Whatever is ultimately developed will have to factor in the current work habits of whoever is inputting data, as DCRI learned while doing its Starbright demonstration project a few years ago, says Woody. “We watched what study coordinators did and, to our surprise, they collected CRF [case report form] data first and then populated the EMR.”

That realization triggered CDISC’s current efforts to “combine workflow” rather than attempt to collect data simultaneously for clinical and research purposes, says Woody. Study coordinators may one day be able to access a CRF while working in an EMR environment with some data items, such as patient demographics, automatically pre-filled.

One complicating factor is that “EDC vendors want to continue to own the space and provide the interface to get the data,” says Woody. The futuristic data-capture model envisioned by CDISC and partner IHE (Integrating the Healthcare Enterprise) “will turn EDC vendors into data stores.” 

________________________________ 

This story first appeared in eCliniqua,one of Bio-IT World’s free e-newsletters. Subscribe here.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.